Last reviewed 2026-04-23 · How we verify

licensed aQIV

aQIV is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four circulating influenza virus strains.

aQIV is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four circulating influenza virus strains. Used for Seasonal influenza prevention in adults.

At a glance

Mechanism of action

aQIV contains inactivated antigens from two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages. It is administered as an intradermal injection using a microinjection system, which targets antigen-presenting cells in the dermis to enhance immunogenicity compared to intramuscular administration.

Approved indications

• Seasonal influenza prevention in adults

Common side effects

• Injection site erythema
• Injection site induration
• Myalgia
• Headache

Key clinical trials

• The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older (PHASE3)
• A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age (PHASE3)
• Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• licensed aQIV CI brief — competitive landscape report
• licensed aQIV updates RSS · CI watch RSS
• Seqirus portfolio CI